The Food and Drug Administration recently authorized the temporary import of hydromorphone hydrochloride injection from Canada to address a critical shortage of the drug, an opioid pain medication. This product is marketed in Canada, and is manufactured in Canada by Sandoz Canada Inc. At this time, no other entity except Hospira is authorized by the FDA to import or distribute Sandoz Hydromorphone Hydrochloride Injection, USP 2 mg/mL ampules in the U.S. See the letter to health care providers for more details. 

Related News Articles

Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…